N/A N=14 Vascular Dysfunction During Physical Inactivity
Aging · Vascular Endothelium · Skeletal Muscle
Primary: Brachial Artery Vascular Function — 5.1; 3.1; 4.4 percent vasodilation
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=20 Sex Differences in Vascular Responses to Exercise
Aging
Primary: Change in FMD in Response to Chronic HIIT — 0.11; 0.57; 0.81; 0.10 % flow mediated dilation
Phase 3 N=76 ARREST PAD (Peripheral Arterial Disease)
Arterial Occlusive Disease · Intermittent Claudication · Insulin Resistance
Primary: Lower Extremity Skeletal Muscle Glucose Uptake — 62.9; 48.6; 49.5 umol/kg/min
N/A N=19 Endothelial Function in Lower Extremity Bypass Grafts
Peripheral Arterial Disease
Primary: Change From Baseline in Saphenous Vein Bypass Graft Vasodilation — 5.28 vein bypass graft size increase (%)
Phase 2 N=26 CD36 in Nutrient Delivery and Its Dysfunction
Insulin Resistance · Endothelial Dysfunction
Primary: Change in Microvascular Blood Volume (MBV) During Insulin Infusion — 13.16; 11.3 ml/kg
N/A N=61 Endothelial Dysfunction in Obese Children
Obesity · Atherosclerosis
Primary: Change From Baseline in Reactive Hyperemia Index at 5 and 10 Months — 1.9; 1.5; 2.01; 1.55 arbitrary units — p=<0.05
Phase 2 N=15 Long Term Nitric Oxide Bioavailability on Vascular Health in Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Change in Flow Mediated Dilation — 0.26; -1.5 percentage of flow mediated dilation
Phase 2 N=34 Sex-related Differences in Arterial Stiffness in Type 2 Diabetics: Role of Uric Acid
Diabetes Mellitus, Type 2 · Hyperuricemia
Primary: Carotid Femoral Pulse Wave Velocity (cfPWV) — 8.71; 7.8; 8.28 m/s
N/A N=70 Mechanisms of Endothelial Cell Dysfunction in Sleep Apnea
Obstructive Sleep Apnea · Hypoxemia
Primary: ODI — 24.71; .97 events/hour
N/A N=14 Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients
Peripheral Arterial Disease · Peripheral Artery Disease
Primary: Endothelial Function — 6.13; 3.78 % dilation
Phase 2 N=19 Blood Flow and Vascular Function in Cystic Fibrosis
Cystic Fibrosis
Primary: Acute Study: Percentage Flow-Mediated Dilation (FMD) — 7.8; 7.7; 7.3; 6.6 percent flow mediated dilation
N/A N=20 Metabolic Acidosis and Vascular Function in Patients With Chronic Kidney Disease
Metabolic Acidosis · Chronic Kidney Disease
Primary: Change in Brachial Artery Flow Mediated Dilation (FMD) — 1.1; -0.7 absolute change in percent FMD
N/A N=21 Dietary Nitrates and Vascular Function in Patients With Peripheral Artery Disease
Peripheral Artery Disease
Primary: Change in Vasodilator Capacity — 16.2; 16.4; 16.5; 14.2 ml/100ml tissue/min
Phase 2 N=31 Red Blood Cell ATP Release and Vascular Function in Humans
Cardiovascular Diseases
Primary: Forearm Blood Flow Responses to Hypoxia After Administration of Intervention — 6.3; 6.2; 2.1; 8.4 mL/min — p=0.97
N/A N=13 FFA-Induced Hypertension and Endothelial Dysfunction
Endothelial Dysfunction · Hypertension
Primary: Change in Systolic Blood Pressure to After Completing an 8-hour Normal Saline Infusion in Obese Normotensive Subjects. — 13 mmHg
N/A N=89 Comparing Blood Vessel Endothelial Function in HIV-Infected People and Matched HIV-Uninfected People
HIV Infection
Primary: Endothelial Function (Brachial Artery Reactivity) — 3.98; 3.37 percent dilation — p=0.10
N/A N=60 Nitric Oxide Bioavailability in Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Disease, Chronic Obstructive
Primary: Flow-Mediated Dilation (FMD) — 3.1; 6.7; 4.7; 6.9 percentage of change in FMD — p=<0.05
N/A N=60 Arterial Stiffness in Type I Diabetes Mellitus
Arterial Stiffness in Youth With Type 1 Diabetes
Primary: Determine the Difference Between Acute Effect of a Mixed Meal on Radial Artery Stiffness in Subjects With Type I Diabetes Mellitus Who do and Who do Not Take an…
Early Phase 1 N=26 Sex Differences in the Dilatory Response of Compound 21
Sex Differences
Primary: Microvascular AT2R Sensitivity Following Local Control Treatment — 15; 25 percentage of maximal blood flow
N/A N=88 HIV-1, Insufficient Sleep and Vascular Endothelial Dysfunction
HIV-1
Primary: Phase 1: Forearm Blood Flow (FBF) Response to Acetylcholine (ACh) — 4.6; 4.2; 11.7; 9.9 mL/100 mL tissue/min
N/A N=80 Uric Acid and the Endothelium in CKD
Kidney Disease
Primary: Change in Endothelial Dependent Dilation From Baseline to Week 12 — 0.2; 0.9 % change — p=0.47
Phase 3 N=61 Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
ADPKD
Primary: Change From Baseline in Flow Mediated Dilation at 6 Months. — -0.2; -0.4 Percent change.
N/A N=4 Phosphodiesterase Type 5 Inhibition to Improve Endothelial Function and Vascular Remodeling in Chronic Kidney Disease and End Stage Renal Disease Patients Requiring New Arteriovenous Fistula
Improve Endothelial Function and Decrease Vascular Stenosis
Primary: Change in Baseline and 2 Week FMD/VP Measurements Between Sildenafil Group and Placebo Group — 10.8; 8.6 Change in FMD%
Phase 3 N=128 Vitamin D and Arterial Function in Patients With Chronic Kidney Disease
Arterial Dysfunction · Chronic Kidney Disease
Primary: Compare the Difference Between the Calcitriol and Cholecalciferol Groups in Conduit Artery Endothelium-dependent Dilation (EDD) in Response to Treatment. — -0.5; 0.3…
Phase 3 N=47 Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Diabetic Patients and CAD
Diabetes, Type I · Diabetes, Type II · Angina
Primary: Change in Post-exercise Coronary Vasodilator Reserve — -4; 2 % change
Phase 3 N=137 ENAC Blockade and Arterial Stiffness
Overweight and Obesity · Insulin Resistance
Primary: Carotid Femoral Pulse Wave Velocity — 7.25; 6.80; 7.12; 6.81 m/s
Phase 2 N=10 Rilonacept to Improve Artery Function in Patients With Atherosclerosis
Coronary Artery Disease · Atherosclerosis · Inflammation
Primary: C-Reactive Protein (CRP) — 3.7; 4.6 mg/L
N/A N=47 Influence of Endothelial Function on Central and Peripheral Causes Of Exercise Impairment in Type 2 Diabetes
Type 2 Diabetes
Primary: Percent Change in Circumferential Strain Before and After Exercise at Baseline, After Vitamin C Infusion, and After Exercise Training — -24; -20; -23; -21 percentage of…
N/A N=202 Dietary Intervention and Vascular Function
Cardiovascular Disease
Primary: Percent Change in Flow Mediated Dilatation (FMD) — -0.39; -0.07; -0.08 post-occlusion diameter change as % — p=0.238
N/A N=33 RAAS and Arterial Stiffness in SCI
Arterial Stiffness · Renin Angiotensin Aldosterone System · Orthostatic Hypotension
Primary: Pulse Wave Velocity (m/s) — 8.81; 7.36; 5.53 m/s